Cancer Immunotherapy: are the Results Discouraging? Can They be Improved?
- 1 January 1992
- book chapter
- Published by Elsevier
- Vol. 59, 245-322
- https://doi.org/10.1016/s0065-230x(08)60308-5
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Cytotoxic activity toward mouse melanoma following immunization of mice with transfected cells expressing a human melanoma-associated antigenCancer Immunology, Immunotherapy, 1991
- Potentiation of delayed-type hypersensitivity response to syngeneic tumors in mice prevaccinated with cells modified by hydrostatic pressure and crosslinkingCancer Immunology, Immunotherapy, 1991
- Phototoxic liposomes coupled to an antibody that alone cannot modulate its cell-surface antigen kill selected target cellsCancer Immunology, Immunotherapy, 1990
- Icam ‐ melanoma cells are relatively resistant to cd3‐mediated t‐cell lysisInternational Journal of Cancer, 1990
- Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccineCancer Immunology, Immunotherapy, 1990
- Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytesCancer Immunology, Immunotherapy, 1990
- Drug Delivery Systems. 1. Site‐Specific Drug Delivery Using Liposomes as CarriersThe Journal of Clinical Pharmacology, 1989
- Cytostatic and cytotoxic activity of lymphokine-activated killer cell supernatantsCancer Immunology, Immunotherapy, 1989
- Potentiation of adoptive immunotherapy by cis‐diamminedichloroplatinum(II), but not by doxorubicin, on a disseminated mouse lymphoma and its association with reduction of tumor burdenInternational Journal of Cancer, 1988
- Immunogenicity of a polyvalent melanoma antigen vaccine in humansCancer, 1988